Company intelligence / Profile preview
Life Biosciences
- Ownership
- Private
- Employees
- ~13
- Development stage
- Preclinical
Overview
Life Biosciences develops therapies that target fundamental biological mechanisms underlying aging. Its most advanced programs are preclinical, with IND-enabling studies ongoing and first-in-human trials expected soon. The company’s platforms have shown promise in reversing cellular aging processes in preclinical models, particularly through partial epigenetic reprogramming using Yamanaka factors. Lead programs target ophthalmic conditions related to aging; additional pipeline assets address broader age-related diseases.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small moleculesGene therapy (AAV-based)Cellular rejuvenation/epigenetic reprogramming
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Life Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Life Biosciences.